Source: Dermatology Times, May 2025
Key Takeaways
- Molecular testing enhances risk stratification and personalizes treatment plans for melanoma and SCC, surpassing traditional staging methods.
- Gene expression profiling classifies patients into risk categories, influencing follow-up strategies and treatment decisions.
- Molecular diagnostics are increasingly important in SCC, with potential to identify high-risk tumors requiring additional intervention.
A key takeaway from the recent Dermatology Times Case-Based Peer Perspective custom video series Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma is that integrating molecular testing into routine clinical practice can significantly enhance risk stratification and guide personalized treatment plans. Led by David Cotter, MD, PhD, a board-certified dermatologist practicing in Las Vegas, Nevada, the series emphasizes that traditional staging methods, though useful, often fall short in capturing the full spectrum of a patient’s risk, especially in complex cases.